RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…
Matched conditions: RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a personalized cell therapy called CAR T-cells for people with relapsed or hard-to-treat lymphoma or acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusin…
Matched conditions: RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for tough leukemia: CAR t cell trial opens for adults
Disease control Recruiting nowThis study is testing a new type of immunotherapy called CAR T cells for adults (ages 18-75) with a hard-to-treat blood cancer called acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The treatment involves taking a patient's own immun…
Matched conditions: RELAPSED REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: King Faisal Specialist Hospital & Research Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC